Esophageal Neuroendocrine Tumor
Associated Genetic Biomarkers
NCI Definition: A well differentiated, low or intermediate grade tumor with neuroendocrine differentiation that arises from the esophagus. 
Of the biomarker-directed therapies for esophageal neuroendocrine tumor, 1 is FDA-approved in at least one setting and 0 have NCCN guidelines in at least one setting .
There is 1 clinical trial for esophageal neuroendocrine tumor, of which 1 is open and 0 are completed or closed. Of the trial that contains esophageal neuroendocrine tumor as an inclusion criterion, 1 is phase 2 (1 open).
Abemaciclib is the most common intervention in esophageal neuroendocrine tumor clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.